Algorithms
Breast Cancer
2022
2023
2024
Lung Cancer
2023
GU
2023
2024
GI
2022
2023
2024
Hematology
2023
2024
Melanoma
2023
2024
Supportive Care
Skin
TNBC
Conferences
ASCO
2022
2023
2024
ESMO
2022
2023
SABCS
2022
2023
ASH
2022
2023
WCLC
GI ASCO
2024
GU ASCO
2023
2024
WLC
2022
2023
AACR
Journal club
Breast
2022
2023
2024
GI
2023
2024
GU
2023
2024
Hematology
2023
2024
Contact
Algorithms
Breast Cancer
2022
2023
2024
Lung Cancer
2023
GU
2023
2024
GI
2022
2023
2024
Hematology
2023
2024
Melanoma
2023
2024
Supportive Care
Skin
TNBC
Conferences
ASCO
2022
2023
2024
ESMO
2022
2023
SABCS
2022
2023
ASH
2022
2023
WCLC
GI ASCO
2024
GU ASCO
2023
2024
WLC
2022
2023
AACR
Journal club
Breast
2022
2023
2024
GI
2023
2024
GU
2023
2024
Hematology
2023
2024
Contact
Search
Journal club
Breast
Explore All
>
Dr. Hope Rugo discusses Capivasertib FDA Approval based on CAPItello-291 Study
EMERALD lead to the Elacestrant FDA Approval - OncBrothers in discussion w/ Dr. Virginia Kaklamani
EMERALD Ph III Study in discussion w/(now FDA Approved) Dr. Aditya Bardia
DESTINY-Breast04 Study Discussion with Dr. Shanu Modi
GI
Explore All
>
FRESCO2 Study: FDA Approval of Fruquintinib for Refractory Colorectal Cancer
MOUNTAINEER Study in discussion w/ Dr. Tanios Bekaii-Saab
The NICHE-2 Study Discussion with Dr. Myriam Chalabi
GU
Explore All
>
Breakthrough in Bladder Cancer: FDA approval – Enfortumab Vedotin + Pelbrolizumab with Dr. Tom Powles
EV-103 Study by Dr. Jonathan Rosenberg led to the FDA Approval of Enfortumab + Pembrolizumab
Hematology
Explore All
>
How to Treat Chronic Myeloid Leukemia (CML) - Dr. Jorge Cortes
Zanubrutinib – FDA Approval, Efficacy & Safety Profile – Discussion with Dr. Shadman
Polatuzumab FDA Approval in DLBCL (POLARIX) & SWOG S1826 Nivo vs. BV in Hodgkin’s Lymphoma Dr. Jonathan Friedberg
Your experience on this site will be improved by allowing cookies
Cookie Policy
Allow cookies